215 related articles for article (PubMed ID: 20438801)
1. Establishment of a new Glivec-resistant chronic myeloid leukemia cell line, SNUCML-02, using an in vivo model.
Park J; Kim KI; Koh Y; Won NH; Oh JM; Lee DS; Kim BK; Ahn KS; Yoon SS
Exp Hematol; 2010 Sep; 38(9):773-81. PubMed ID: 20438801
[TBL] [Abstract][Full Text] [Related]
2. Establishment and characterization of an STI571-resistant human myelogenous leukemia cell line, SR-1.
Kwon HC; Kim SH; Kim JS; Han H; Roh MS; Han JY; Seo SY; Lee YH; Kim HJ
Cancer Genet Cytogenet; 2004 Oct; 154(1):52-6. PubMed ID: 15381372
[TBL] [Abstract][Full Text] [Related]
3. Analysis of gene expression profiles in an imatinib-resistant cell line, KCL22/SR.
Ohmine K; Nagai T; Tarumoto T; Miyoshi T; Muroi K; Mano H; Komatsu N; Takaku F; Ozawa K
Stem Cells; 2003; 21(3):315-21. PubMed ID: 12743326
[TBL] [Abstract][Full Text] [Related]
4. Establishment of a new Philadelphia chromosome-positive acute lymphoblastic leukemia cell line (SK-9) with T315I mutation.
Okabe S; Tauchi T; Ohyashiki K
Exp Hematol; 2010 Sep; 38(9):765-72. PubMed ID: 20471447
[TBL] [Abstract][Full Text] [Related]
5. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
6. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV
Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063
[TBL] [Abstract][Full Text] [Related]
7. Rapid detection of phosphotyrosine proteins by flow cytometric analysis in Bcr-Abl-positive cells.
Desplat V; Lagarde V; Belloc F; Chollet C; Leguay T; Pasquet JM; Praloran V; Mahon FX
Cytometry A; 2004 Nov; 62(1):35-45. PubMed ID: 15468123
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of phosphotyrosine phosphatase 1B causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571.
Koyama N; Koschmieder S; Tyagi S; Portero-Robles I; Chromic J; Myloch S; Nürnberger H; Rossmanith T; Hofmann WK; Hoelzer D; Ottmann OG
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2025-31. PubMed ID: 16609011
[TBL] [Abstract][Full Text] [Related]
9. Cytogenetic and molecular mechanisms of resistance to imatinib.
Hochhaus A
Semin Hematol; 2003 Apr; 40(2 Suppl 2):69-79. PubMed ID: 12783379
[TBL] [Abstract][Full Text] [Related]
10. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
Nguyen TK; Rahmani M; Gao N; Kramer L; Corbin AS; Druker BJ; Dent P; Grant S
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2239-47. PubMed ID: 16609040
[TBL] [Abstract][Full Text] [Related]
11. Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells.
Gottschalk S; Anderson N; Hainz C; Eckhardt SG; Serkova NJ
Clin Cancer Res; 2004 Oct; 10(19):6661-8. PubMed ID: 15475456
[TBL] [Abstract][Full Text] [Related]
12. ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms.
Kuroda J; Kimura S; Andreeff M; Ashihara E; Kamitsuji Y; Yokota A; Kawata E; Takeuchi M; Tanaka R; Murotani Y; Matsumoto Y; Tanaka H; Strasser A; Taniwaki M; Maekawa T
Br J Haematol; 2008 Jan; 140(2):181-90. PubMed ID: 18028486
[TBL] [Abstract][Full Text] [Related]
13. Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status.
Frater JL; Tallman MS; Variakojis D; Druker BJ; Resta D; Riley MB; Hrisinko MA; Peterson LC
Am J Clin Pathol; 2003 Jun; 119(6):833-41. PubMed ID: 12817431
[TBL] [Abstract][Full Text] [Related]
14. A novel mechanism for imatinib mesylate (STI571) resistance in CML cell line KT-1: role of TC-PTP in modulating signals downstream from the BCR-ABL fusion protein.
Shimizu T; Miyakawa Y; Iwata S; Kuribara A; Tiganis T; Morimoto C; Ikeda Y; Kizaki M
Exp Hematol; 2004 Nov; 32(11):1057-63. PubMed ID: 15539083
[TBL] [Abstract][Full Text] [Related]
15. BCR-ABL gene amplification and overexpression in a patient with chronic myeloid leukemia treated with imatinib.
Gadzicki D; von Neuhoff N; Steinemann D; Just M; Büsche G; Kreipe H; Wilkens L; Schlegelberger B
Cancer Genet Cytogenet; 2005 Jun; 159(2):164-7. PubMed ID: 15899391
[TBL] [Abstract][Full Text] [Related]
16. Contribution of BCR-ABL-independent activation of ERK1/2 to acquired imatinib resistance in K562 chronic myeloid leukemia cells.
Nambu T; Araki N; Nakagawa A; Kuniyasu A; Kawaguchi T; Hamada A; Saito H
Cancer Sci; 2010 Jan; 101(1):137-42. PubMed ID: 19843070
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
[TBL] [Abstract][Full Text] [Related]
18. Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein.
Scappini B; Gatto S; Onida F; Ricci C; Divoky V; Wierda WG; Andreeff M; Dong L; Hayes K; Verstovsek S; Kantarjian HM; Beran M
Cancer; 2004 Apr; 100(7):1459-71. PubMed ID: 15042680
[TBL] [Abstract][Full Text] [Related]
19. Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR/ABL-positive cell line.
Ricci C; Scappini B; Divoky V; Gatto S; Onida F; Verstovsek S; Kantarjian HM; Beran M
Cancer Res; 2002 Nov; 62(21):5995-8. PubMed ID: 12414617
[TBL] [Abstract][Full Text] [Related]
20. Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair.
Majsterek I; Sliwinski T; Poplawski T; Pytel D; Kowalski M; Slupianek A; Skorski T; Blasiak J
Mutat Res; 2006 Jan; 603(1):74-82. PubMed ID: 16388976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
